These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12941143)

  • 21. Characterization of Schistosoma japonicum tetraspanning orphan receptor and its role in binding to complement C2 and immunoprotection against murine schistosomiasis.
    Ma S; Zai J; Han Y; Hong Y; Zhang M; Cao X; Han Q; Lu K; Zhao Z; Lin J; Fu Z
    Parasit Vectors; 2017 Jun; 10(1):288. PubMed ID: 28599669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The human complement system: assembly of the classical pathway C3 convertase.
    Kerr MA
    Biochem J; 1980 Jul; 189(1):173-81. PubMed ID: 6906228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
    Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata.
    Nunn MA; Sharma A; Paesen GC; Adamson S; Lissina O; Willis AC; Nuttall PA
    J Immunol; 2005 Feb; 174(4):2084-91. PubMed ID: 15699138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for a C4b binding site on the C2b domain of C2.
    Oglesby TJ; Accavitti MA; Volanakis JE
    J Immunol; 1988 Aug; 141(3):926-31. PubMed ID: 3397535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A nanobody-based complement inhibitor targeting complement component 2 reduces hemolysis in a complement humanized mouse model of autoimmune hemolytic anemia.
    Chen JY; Zhang L; Luo L; Yang M; Chen Y; Lin F
    Clin Immunol; 2023 Aug; 253():109678. PubMed ID: 37315680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure and activation of complement components C2 and factor B.
    Gagnon J
    Philos Trans R Soc Lond B Biol Sci; 1984 Sep; 306(1129):301-9. PubMed ID: 6149575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Complin, a novel complement inhibitor that targets complement proteins factor B and C2.
    Kadam AP; Sahu A
    J Immunol; 2010 Jun; 184(12):7116-24. PubMed ID: 20483772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purification and characterization of the C3 convertase of the classical pathway of human complement system by size exclusion high-performance liquid chromatography.
    Nagasawa S; Kobayashi C; Maki-Suzuki T; Yamashita N; Koyama J
    J Biochem; 1985 Feb; 97(2):493-9. PubMed ID: 3874204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The crystal structure of C2a, the catalytic fragment of classical pathway C3 and C5 convertase of human complement.
    Krishnan V; Xu Y; Macon K; Volanakis JE; Narayana SV
    J Mol Biol; 2007 Mar; 367(1):224-33. PubMed ID: 17234210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemolytic efficiency of cell-bound IgM: evidence that IgM-C1 complexes activate C4 molecules not hemolytic with homologous C2--C9.
    Ejzemberg R; Borsos T
    J Immunol; 1982 Apr; 128(4):1600-2. PubMed ID: 7061844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
    Loos M; Heinz HP
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of C3 convertase in the rat classical complement pathway.
    Naito A; Okada H
    Microbiol Immunol; 1997; 41(8):621-4. PubMed ID: 9310942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The bovine complement system.
    Linscott WD; Triglia RP
    Adv Exp Med Biol; 1981; 137():413-30. PubMed ID: 7331946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.
    Kumar J; Yadav VN; Phulera S; Kamble A; Gautam AK; Panwar HS; Sahu A
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the component and regulatory proteins of the classical pathway C3 convertase.
    Welch TR; Forristal J; Beischel L
    J Lab Clin Med; 1986 Jun; 107(6):529-33. PubMed ID: 3635565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
    Gigli I; Fujita T; Nussenzweig V
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b.
    Nagasawa S; Stroud RM
    Proc Natl Acad Sci U S A; 1977 Jul; 74(7):2998-3001. PubMed ID: 70787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Determination of proteinase activity of complement system by immunoenzyme methods].
    Romanov SV; Kozlov LV; D'iakov VL; Batalova TN; Guzova VA
    Biomed Khim; 2003; 49(6):604-12. PubMed ID: 16119089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.